Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,852 result(s) found for: Breast cancer. Displaying page 20 of 93.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next» Last»»
    EudraCT Number: 2011-001024-38 Sponsor Protocol Number: AIO-MAM-0110 Start Date*: 2011-07-27
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Vinorelbine In Combination with the mTOR Inhibitor Everolimus vs Vinorelbine monotherapy in Advanced breast cancer
    Medical condition: local advanced metastatic breat cancer, second line therapy for patients who did not respond to treatment with anthracyclines or taxanes or are not suitable for such treatment
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001040-62 Sponsor Protocol Number: GBG78/BIG1-13 Start Date*: 2013-11-14
    Sponsor Name:GBG Forschungs GmbH
    Full Title: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in patients with hormone-receptor positive, HER2 normal primary breast cancer with high relapse r...
    Medical condition: About one-third of patient with hormone-receptor positive, HER2 negative breast cancer and residual disease after standard of care - including adequate surgery - have a substantial risk of relapse ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071113 Node-positive breast cancer LLT
    21.1 100000004865 10025025 Lumpectomy (breast cancer) LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073289 Premenopausal breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-002114-36 Sponsor Protocol Number: 20110113 Start Date*: 2011-10-04
    Sponsor Name:Amgen Inc
    Full Title: Open-Label Access Protocol of Denosumab for Subjects with Advanced Cancer
    Medical condition: Bone Metastases in Subjects with Advanced Breast Cancer and Bone Metastases in Men with Hormone-Refractory Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) AT (Completed) FR (Completed) ES (Completed) PL (Completed) BE (Completed) LV (Completed) LT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000960-52 Sponsor Protocol Number: 107CS-6 Start Date*: 2020-11-20
    Sponsor Name:Daehwa Pharmaceutical Co., Ltd.
    Full Title: A Multi-national, Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patient...
    Medical condition: Recurrent or metastatic HER2 negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001864-12 Sponsor Protocol Number: IRFMN-BRC-6992 Start Date*: 2018-02-09
    Sponsor Name:IRCCS - Istituto di Ricerche Farmacologiche Mario Negri
    Full Title: International, multicenter, phase II, randomized, parallel-arm trial investigating the role of two different metronomic chemotherapy regimens in locally advanced or metastatic triple negative breas...
    Medical condition: Locally advanced or metastatic triple negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019216-20 Sponsor Protocol Number: AZ2010 Start Date*: 2010-05-01
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
    Full Title: "Effects of drug treatment with bisphosphonates (zoledronic acid) in the prevention of skeletal events in breast cancer patients with osteoporosis. Significant correlation with some biological para...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003442-32 Sponsor Protocol Number: ML28589 Start Date*: 2013-01-08
    Sponsor Name:ROCHE SAS
    Full Title: AN OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE III STUDY IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER RESPONDING TO FIRST LINE TREATMENT WITH INTRAVENOUS TRASTUZUMAB FOR AT LEAST 3 YEARS A...
    Medical condition: HER2-positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006252-21 Sponsor Protocol Number: 3160A6-2207-WW Start Date*: 2009-05-28
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: A Phase 2, Randomized, Open-label Study of Bosutinib Administered in Combination With Letrozole Versus Letrozole Alone as First Line Therapy in Post-Menopausal Women With Locally Advanced or Metast...
    Medical condition: Locally advanced or metastatic ER+/PgR+/erbB2-breast cancer in post-menopausal women
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BE (Completed) GB (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-006109-19 Sponsor Protocol Number: STM01-102 Start Date*: 2006-09-08
    Sponsor Name:Sopherion Therapeutics, Inc.
    Full Title: A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First line Therapy of Metastatic Breast Cancer
    Medical condition: HER2+ Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027475 llt
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Completed) DE (Completed) ES (Prematurely Ended) GB (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004734-22 Sponsor Protocol Number: WO39392 Start Date*: 2017-09-06
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE/NAB-PACLITAXEL-BASED CHEMOTHERAPY COMPARED WI...
    Medical condition: Triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039850 Secondary malignant neoplasm of breast LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001765-41 Sponsor Protocol Number: 1200.137 Start Date*: 2012-02-13
    Sponsor Name:Medizinische Fakultät der Otto-von-Guericke Universität Magdeburg Universitätsklinikum Magdeburg A.ö.R.
    Full Title: Single-arm, open-label, multicentre phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast ca...
    Medical condition: Metastatic breast cancer patients with intermediate HER2 expression (IHC 2+, HER2 FISH-negative)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002924-18 Sponsor Protocol Number: CYC065-101 Start Date*: 2021-10-08
    Sponsor Name:Cyclacel Pharmaceuticals
    Full Title: A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Ly...
    Medical condition: Endometrial cancer, Ovarian cancer, Biliary tract cancer, Hepatocellular carcinoma, B-cell lymphoma, T-cell lymphoma, Metastatic colorectal cancer, Breast cancer (metastatic HER-2 refractory, Horm...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014735 Endometrial cancer NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033130 Ovarian cancer NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025734 Malignant neoplasm of biliary tract, part unspecified LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083234 Hormone receptor positive breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004988-19 Sponsor Protocol Number: fides Start Date*: 2008-07-31
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: A PHASE II STUDY, COMPARING A DOSE-TITRATION REGIMEN OF FULVESTRANT WITH THE APPROVED DOSING REGIMEN IN POSTMENOPAUSAL PATIENTS WITH HORMONE-RESPONSIVE ADVANCED BREAST CANCER (ABC)
    Medical condition: Post-menopausal women with advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014662-26 Sponsor Protocol Number: IRST 174.04 Start Date*: 2009-11-06
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
    Full Title: Phase II comparative study of Myocet plus Cyclophosphamide plus metformin versus Myocet plus Cyclophosphamide in first line treatment of HER2 negative metastatic breast cancer patients.
    Medical condition: HER2 negative metastatic breast cancer patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000380-13 Sponsor Protocol Number: CP-MGAH22-04 Start Date*: 2015-09-02
    Sponsor Name:MacroGenics, Inc.
    Full Title: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 The...
    Medical condition: Metastatic or Locally Advanced HER2-positive Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) CZ (Completed) AT (Completed) FI (Completed) ES (Completed) DK (Completed) FR (Ongoing) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000677-23 Sponsor Protocol Number: CLCL161A2201 Start Date*: 2012-10-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer
    Medical condition: Triple negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) IE (Completed) IT (Completed) BE (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000579-12 Sponsor Protocol Number: D4200L00009 Start Date*: 2008-12-03
    Sponsor Name:ASTRAZENECA
    Full Title: A randomised, double-blind, parallel-group, multicentre, phase ii study to evaluate the safety and pharmacological activity of the combination of Vandetanib (100 or 300 mg/daily or placebo) with Fu...
    Medical condition: Postmenopausal women with advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006026-10 Sponsor Protocol Number: IEOS381/607 Start Date*: 2008-04-02
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: PREOPERATIVE ENDOCRINE TREATMENT WITH LETROZOLE ± TRIPTORELIN IN PATIENTS WITH ER AND PgR POSITIVE LOCALLY ADVANCED BREAST CANCER
    Medical condition: LOCALLY ADVANCED BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023763-17 Sponsor Protocol Number: GDC4950g Start Date*: 2012-05-18
    Sponsor Name:Genentech, Inc.
    Full Title: A phase II double-blind placebo-controlled randomized study of GDC-0941 or GDC-0980 with Fulvestrant versus Fulvestrant in advanced or metastatic breast cancer in patients resistant to aromatase in...
    Medical condition: Advanced or metastatic breast cancer resistant to aromatase inhibitor therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) CZ (Completed) GB (Prematurely Ended) DK (Prematurely Ended) HU (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001267-33 Sponsor Protocol Number: A6181107 Start Date*: 2006-10-11
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: Phase III Randomized, Multi Center Study of Sunitinib Malate (SU 011248) or Capecitabine in Subjects with Advanced Breast Cancer who failed both a taxane and an anthracycline chemotherapy regimen o...
    Medical condition: Histologically or cytologically proven diagnosis of breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) GB (Completed) BG (Completed) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 22 19:06:47 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA